BL 1220

Drug Profile

BL 1220

Alternative Names: BL-1220

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ben Gurion University; Hadassah Medical Organization
  • Developer BioLineRx
  • Class Hepatoprotectants; Sodium compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver failure; Non-alcoholic steatohepatitis

Most Recent Events

  • 23 Sep 2016 BioLineRx in-licenses technology from BGN Technologies and Hadasit for use in Liver treatment
  • 23 Sep 2016 BioLineRx is developing BL 1220 under an exclusive worldwide licensing agreement with BGN Technologies and Hadasit
  • 23 Sep 2016 Preclinical trials in Liver failure in Israel (PO) before Sep 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top